Bengaluru-based Biocon gears up for a landmark fiscal year as it eyes leadership in global insulin and obesity drug markets.
In a recent interview with Moneycontrol, Biocon Group Chairperson Kiran Mazumdar-Shaw projected FY26 as an acceleration year for the company, driven by strategic gains across its core businesses—biosimilars, generics, and research services. With a surge in global demand for insulin and GLP-1 drugs, Biocon is positioning itself to become a key global supplier, filling critical gaps left by major pharma players shifting focus toward high-margin therapies.
“When you look into FY26, I think we will see some very strong growth in all of our businesses,” said Mazumdar-Shaw.
Filling the Global Insulin Gap
As leading pharma companies scale down their insulin portfolios to chase the booming GLP-1 segment, Biocon is stepping in with expanded insulin manufacturing capacity in Malaysia and full-stack capabilities. This strategic move places Biocon as a rare global player ready to meet unmet insulin demands, especially in emerging markets.
Targeting the GLP-1 Gold Rush
Biocon’s recent UK launch of liraglutide—a GLP-1 receptor agonist for diabetes and obesity—marks the beginning of a broader push into Europe and the U.S. by FY26. The company is also preparing for the launch of semaglutide in emerging markets next year, amplifying its footprint in the exploding weight loss and diabetes therapeutics space.
“Biocon has a huge opportunity in GLP-1 starting with liraglutide this year. But even a bigger one is starting end of next year, which is semaglutide in emerging markets,” said Mazumdar-Shaw.
Strengthening Generics and Biosimilars Pipeline
The Generics division is set for a rebound in FY26, powered by operational efficiencies, API cost improvements, and several upcoming launches. Although Lenalidomide supplies were significant in Q4 FY25, the focus now shifts to new products ahead of unlimited Lenalidomide volumes from January 2026.
Meanwhile, Biocon Biologics is preparing to launch five new biosimilars in the next 12–18 months, including products for Stelara (ustekinumab), Bevacizumab, Aspart, Aflibercept, and Denosumab. The company’s U.S. launch of ustekinumab is already underway, with Aflibercept expected in H2 2026.
Research Services Maintain Momentum
Biocon’s research arm Syngene continues its upward trajectory, projecting mid-single-digit revenue growth into FY26, riding on the momentum from a strong second half in FY25.
An Inflexion Point
FY25 marked a strategic turning point for Biocon, laying the groundwork for sustained acceleration. With significant investments across manufacturing, R&D, and global partnerships, the company is now poised to capitalize on scale, innovation, and global market needs.
